{"name":"Mesoblast, Inc.","slug":"mesoblast-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Standard of Care for GVHD","genericName":"Standard of Care for GVHD","slug":"standard-of-care-for-gvhd","indication":"Graft-versus-host disease","status":"phase_3"},{"name":"Allogeneic Mesenchymal Precursor Cells","genericName":"Allogeneic Mesenchymal Precursor Cells","slug":"allogeneic-mesenchymal-precursor-cells","indication":"Other","status":"phase_2"},{"name":"Prochymal®","genericName":"Prochymal®","slug":"prochymal","indication":"Graft-versus-host disease","status":"phase_3"},{"name":"Provacel","genericName":"Provacel","slug":"provacel","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rexlemestrocel-L + HA Mixture","genericName":"Rexlemestrocel-L + HA Mixture","slug":"rexlemestrocel-l-ha-mixture","indication":"Knee osteoarthritis","status":"phase_3"}]}],"pipeline":[{"name":"Rexlemestrocel-L + HA Mixture","genericName":"Rexlemestrocel-L + HA Mixture","slug":"rexlemestrocel-l-ha-mixture","phase":"phase_3","mechanism":"Rexlemestrocel-L is an allogeneic mesenchymal stem cell therapy combined with hyaluronic acid that promotes tissue repair and reduces inflammation through paracrine signaling and immunomodulation.","indications":["Knee osteoarthritis","Tendon and ligament injuries"],"catalyst":""},{"name":"Standard of Care for GVHD","genericName":"Standard of Care for GVHD","slug":"standard-of-care-for-gvhd","phase":"phase_3","mechanism":"Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease.","indications":["Graft-versus-host disease"],"catalyst":""},{"name":"Allogeneic Mesenchymal Precursor Cells","genericName":"Allogeneic Mesenchymal Precursor Cells","slug":"allogeneic-mesenchymal-precursor-cells","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prochymal®","genericName":"Prochymal®","slug":"prochymal","phase":"phase_3","mechanism":"Prochymal is a mesenchymal stem cell therapy that aims to modulate the immune system and promote tissue repair.","indications":["Graft-versus-host disease"],"catalyst":""},{"name":"Provacel","genericName":"Provacel","slug":"provacel","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOMkZCM0dlR05LZm13cG9mSUw2Q0ZZb0xGZlNGa0U0SVY0M1JhYjRTeE9wcGlaM1dMaXVmU1BlNHRlbGk5Z3RQQjcxQlJYLVFtMnp0NC1Fd0RySDRTN2YtNGFuZ3JyOW5vdTZVOExwaS1tZHE1LTkwSWhYYUpxVnE3RnpydjVSMk44dWxjU3NUcHhIaG5ubjl5MHFzYjRPcE1qMUJ1dVhfQklidkNET0NjbEpwNlpHby04MHYyUm1GcVFOVXRuTkhpLTlZcTJxZ3NONklVNEljYVVOdllCdHdDOVBaMA?oc=5","date":"2026-04-08","type":"pipeline","source":"Sahm","summary":"Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm","headline":"Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOWXc0ZjBGVlJLaDUwWHBKUHBGNV9CNlpNeEREVE55MVJ5Qk1Rakd4MUdKM1BYNVJRS3NZd1VMNEx2ZVMyX3R4RFB2bDRQdUlDcHY3bTlaX09LQUxXalhSemItZFdLSkhDbWtMazkzLXlYd19kcUJhQUJMcTU1ODhrOF9GSnc0eDk3ZlNScURnWDc5VWs?oc=5","date":"2026-03-23","type":"pipeline","source":"The Motley Fool Australia","summary":"3 top ASX shares that could double in value from here - The Motley Fool Australia","headline":"3 top ASX shares that could double in value from here","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxOamI4SmJMSkJDXzRhb0FVLW5WV2F5VmgwclJ4STFuREoxVExoUjgtdW02NlNrUEJ4R0JieDNlbDd5RFNPNWNPR0YwcEgzVU52a3AzYWlqOFA2ai1XRU9sV1VLRkhoVUdWeEpzYTdleTRSNGI5ZEJlNkFUSkJYRHZLcXRuY29YY25zVm1hYktjYXV1akNMWGc1LUMzZm1LcWlaZEw0d0Y5eWZENmtWdkFkWHdzNFQwQWdOUkdTUW1ZSzVBY25QamJMMUR6eHJlLVVDZWJtSVg5ajVMc2prNUtRYVpYcFRraUtEWHJWaC03SjF1YmxLUTluRGp2NEJYNzFnN2NjV2pzUDE?oc=5","date":"2025-11-26","type":"pipeline","source":"Benzinga","summary":"Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher - Benzinga","headline":"Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPSkRWd2JhZ244TWVfRTFsNkdDd3JxeExDWm1wNUR0dWYyNFN5V012enIwWkJqWGtoNmxtTGtUQmZYUkxBelpyUjgyR1dTYnZjZUV0ZExBanlaeHBQRUpUdzljOExXVEVBaWRNLXdWTmhfSXZIUXl0Rl9ENGdfeFo4TFhGc3V1akg2SEE?oc=5","date":"2025-10-01","type":"pipeline","source":"finance.yahoo.com","summary":"Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs - finance.yahoo.com","headline":"Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQODRSeHZ1WTg0bnVlRGJqRlNEbDQzZGZ6ejQxNGI0amtJR19NQ1dEeFY5Y2x2MkxpU0pMY1VHSlFkNnRpZy02OGcybmNJdW9YcXJJRmcwUnFQMUNhUDNmTWlMbjdoeFdMVTJTVXUtbjUyeERyWHRqT3dJQkx0TklXRjVzUFNQZHU1WFIyNDdpekFXenprZFc3Z3VXM3FhazBVX202Ukk4S01xMTBGem5ZNE9Xc3V0ZHV4MVpDYk4zVWVSTjNfZnVBN0NyWFZNUk13QVF6ckFObUJhajh4QVNsbjJWWGZieVhxQU9LN3VaWFJCcXZMakZUZDU5MjZsQkJmX0FSWWtxNU5JbXdZWTF0Wnc4SlA3SzJweU9LcHBXYXlCTndxTVliSlh0LU9ta3Qtb1ItV2xrZVVta0k2MWc?oc=5","date":"2025-01-30","type":"trial","source":"globenewswire.com","summary":"Chronic Pain Clinical Trial Pipeline Experiences Momentum: - globenewswire.com","headline":"Chronic Pain Clinical Trial Pipeline Experiences Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQU9GZGR2aUYwNm4wRVFTeVJJeFRWMTNidXlUTVpCTVBlTzN1dUo0UW44LUVVamw2UUlNUFJvM3p6VlNabktHaG01MkJsc3h6VEVaTEVrSmhqNHpmU2tlX2RxZFJCN3BpbEVsbWhkTzBzeUtkLUZ0aWtkeTdHV25aczlRYUg4X1o2ekxlakJlMm8xYnVMWndGZjRvTVZOcTZpbEZXQ0Jub3FLaDg?oc=5","date":"2024-12-24","type":"pipeline","source":"BioWorld News","summary":"Mesoblast scores first US nod for mesenchymal stromal cell therapy - BioWorld News","headline":"Mesoblast scores first US nod for mesenchymal stromal cell therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQUVhkQVlIWm5kdU1mN3pfcVFnbzA1ODhBSEd5Q2phWF95bDluQWZjbEhtRDRSTWFvbU81ZHNCTVlGZkQwM1Y0UXBkUGVNRHZpT053VllKS0YzejEyVEJZbmpTckxjZnNGcDJJUUlhdl9PS3dTeFRXN2VJVlRfODNsYVcyVVVjQktEQXo1UlNVeUw2WnpsajhBYm9aa3A?oc=5","date":"2024-12-19","type":"regulatory","source":"Fierce Pharma","summary":"After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy - Fierce Pharma","headline":"After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPWEFMWFJwaE9JZndfcGJ0X3lYT1F0ZEQwUFdwaksybVk1Y3UtVUNLX0l2aUZaaUxROTRiZTZSR3dxejYwLVp4R1JISEZpZkRIQkNoaVBwVkN1NWJNN3JoS05JWFhkMGJTblpucjJRYnV3c0lBM19ZcWNVOWtBYVYtVkJ3TGZqSGlXNG1DdGNNdDQxT1E?oc=5","date":"2024-12-19","type":"pipeline","source":"pharmaphorum","summary":"Mesoblast finally pushes GvHD cell therapy over finish line - pharmaphorum","headline":"Mesoblast finally pushes GvHD cell therapy over finish line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5nN0UwZFN6SS00YWR3UUd6SkxjRHJTdjJqUi1XdmhLbS1CMmlkckFmWjFTRmhkQXRBWVBOdkpyVHowd1Zxem1QbVU5czBRLUNnTVZIMGFhVlRZa0pVY2ZJQlVhWEh2bGk1ZjBXNERFNEpveF94LWlz0gF8QVVfeXFMT0p4dzQ4bXFoMlhaLTBIMFJzVFhpS3FhQmpBX29fSThZZk9hT2hWSlZ2X2xJSDNsTjhZRXJ3bUF3Uk52NWhvUWlhbmVkRGdKTEJnSnJLdUdPY3V3R3FXMXNmbk1UM253d0k4TEN0X2lfb2VfbjJuYzJaZjFVNA?oc=5","date":"2024-08-18","type":"pipeline","source":"BioInformant","summary":"Is the CAR-T Cell Therapy Craze Driving Pharma Investment? - BioInformant","headline":"Is the CAR-T Cell Therapy Craze Driving Pharma Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZ0owUDV3SUR6VlBKak5NMWwtRVdLN1ZWSjlDZV9iNHZNcmlJMUg2QndmUTVuWXdsemFjekRTQXZHVGcxRnJfUDduR0NzVVpEYms3NUFZUnRmR1F4THEzRXZVYjdxcHdId2dGREtoYTZRWHg4M2hVZ0phV2M5M0xIdW0tSlFtVGh2V1hvYzZRdjhUQVlWWmNhZXJwd3VUME10cEY1NVEwYkVWeExvazZ4NFhTUjEtRDZJZVpWT3Q2LXZHQ2Y0OFU2M2JIMFRJaTBkZVptTzJCNGtYUWdw?oc=5","date":"2023-08-04","type":"regulatory","source":"reuters.com","summary":"Mesoblast shares tank after US FDA rejects cell therapy for children - reuters.com","headline":"Mesoblast shares tank after US FDA rejects cell therapy for children","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sZTJDMlBBbW9ST2kza3hSQktSckhrNkI4OVZyRzZ6NG5aZTlRbF9Sa2RDMEpfMzR1ankyTGhoU3k3ZEdGV3M1b081VWN6Q0Rpa3pXYkxON2Vmcmx2RlphZmFubmhqRnZ3?oc=5","date":"2022-12-22","type":"pipeline","source":"Labiotech.eu","summary":"10 biotech companies to watch in 2023 - Labiotech.eu","headline":"10 biotech companies to watch in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQNnZFbFVJenBodlc1YjRvczVoeVBXNWdQRXRQWFRrWkhnTTFRUVplei1ZN0NCaTlyZ18zaVdPdldrSjA2UU9kb01fMnpUNmtzYm05UlMtZF8wNXpmaGRJQ1BwaDhzLXhBcW5oUjU2Qk5nM191YUhiZUhWOG1EcDF0X09ia1JKUUl2UXc?oc=5","date":"2016-12-23","type":"deal","source":"Drug Delivery Business","summary":"Mesoblast gains on A$29m investment deal with Mallinckrodt - Drug Delivery Business","headline":"Mesoblast gains on A$29m investment deal with Mallinckrodt","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}